	US 12,484,608 B2
	Nutritional composition and infant formula for promoting de novo myelination
Nora Schneider, Epalinges (CH); Jonas Hauser, Lausanne (CH); Sean Deoni, Providence, RI (US); Tamas Bartfai, Stockholm (SE); and Jonathan O'Regan, County Kerry (IE)
Assigned to Societe des Produits Nestle S.A., Vevey (CH)
Filed by SOCIETE DES PRODUITS NESTLE S.A., Vevey (CH)
Filed on Apr. 16, 2024, as Appl. No. 18/637,077.
Application 18/637,077 is a continuation of application No. 17/678,672, filed on Feb. 23, 2022, granted, now 11,986,003.
Application 17/678,672 is a continuation of application No. 16/061,121, granted, now 11,297,872, issued on Apr. 12, 2022, previously published as PCT/EP2016/080778, filed on Dec. 13, 2016.
Claims priority of provisional application 62/328,052, filed on Apr. 27, 2016.
Claims priority of provisional application 62/315,224, filed on Mar. 30, 2016.
Claims priority of provisional application 62/315,198, filed on Mar. 30, 2016.
Claims priority of provisional application 62/315,238, filed on Mar. 30, 2016.
Claims priority of provisional application 62/315,187, filed on Mar. 30, 2016.
Claims priority of provisional application 62/315,249, filed on Mar. 30, 2016.
Claims priority of application No. 15199752 (EP), filed on Dec. 14, 2015; application No. 15199757 (EP), filed on Dec. 14, 2015; application No. 15199758 (EP), filed on Dec. 14, 2015; application No. 15199764 (EP), filed on Dec. 14, 2015; and application No. 15199769 (EP), filed on Dec. 14, 2015.
Prior Publication US 2024/0349771 A1, Oct. 24, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A23L 33/00 (2016.01); A23L 33/12 (2016.01); A23L 33/15 (2016.01); A23L 33/16 (2016.01); A24B 15/38 (2006.01); A61K 9/00 (2006.01); A61K 31/14 (2006.01); A61K 31/202 (2006.01); A61K 31/519 (2006.01); A61K 31/661 (2006.01); A61K 31/70 (2006.01); A61K 31/714 (2006.01); A61K 33/00 (2006.01); A61K 33/06 (2006.01); A61K 33/26 (2006.01); A61K 33/30 (2006.01); A61K 33/42 (2006.01); A61K 45/06 (2006.01); A61P 25/28 (2006.01)

CPC A23L 33/40 (2016.08) [A23L 33/12 (2016.08); A23L 33/15 (2016.08); A23L 33/16 (2016.08); A23L 33/30 (2016.08); A24B 15/38 (2013.01); A61K 9/0095 (2013.01); A61K 31/14 (2013.01); A61K 31/202 (2013.01); A61K 31/519 (2013.01); A61K 31/661 (2013.01); A61K 31/70 (2013.01); A61K 31/714 (2013.01); A61K 33/00 (2013.01); A61K 33/06 (2013.01); A61K 33/26 (2013.01); A61K 33/30 (2013.01); A61K 33/42 (2013.01); A61K 45/06 (2013.01); A61P 25/28 (2018.01); A23V 2002/00 (2013.01); A23V 2200/322 (2013.01); A23V 2250/1564 (2013.01); A23V 2250/1578 (2013.01); A23V 2250/1588 (2013.01); A23V 2250/1592 (2013.01); A23V 2250/161 (2013.01); A23V 2250/1618 (2013.01); A23V 2250/1642 (2013.01); A23V 2250/1846 (2013.01); A23V 2250/185 (2013.01); A23V 2250/1852 (2013.01); A23V 2250/1862 (2013.01); A23V 2250/1886 (2013.01); A23V 2250/5424 (2013.01); A23V 2250/7056 (2013.01); A23V 2250/706 (2013.01)]

11 Claims

1. A method for promoting, supporting, or optimizing de novo myelination, brain structure, brain connectivity, intellectual potential, cognitive potential, and/or learning potential and cognitive function in a formula-fed subject, wherein the formula-fed subject is a human infant or child, wherein the brain structure refers to an amount and/or a spatial distribution of myelinated matter throughout the brain of the formula-fed subject and/or within specific brain regions of the formula-fed subject, and wherein the cognitive function is optimized if scores of the formula-fed subject in a standardized neurodevelopmental test are less than one standard deviation different from that of an exclusively breastfed subject born to a well-nourished mother, the method comprising administering a synthetic nutritional composition comprising a phospholipid, a metabolic precursor, and/or a metabolite thereof to the formula-fed subject.